Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis

Digestive Diseases and Sciences

Volumn 61, Issue 9, 2016, Pages 2477-2487

  Popov, Violeta B ^a   Thompson, Christopher C ^b   Kumar, Nitin ^b,c   Ciarleglio, Maria M ^d   Deng, Yanhong ^d   Laine, Loren ^e  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Bariatric Endoscopy Institute Gastroenterology Weight Management   (United States)

^d YALE UNIVERSITY   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intragastric balloon; Liver enzymes; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; LIVER ENZYME; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BALLOON CATHETERIZATION; BODY MASS; CONTROLLED CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; ENZYME BLOOD LEVEL; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRIC BALLOON; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATOGRAPHY; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HISTOLOGY; META ANALYSIS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; BARIATRIC SURGERY; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; LIVER; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; BARIATRIC SURGERY; GAMMA-GLUTAMYLTRANSFERASE; GASTRIC BALLOON; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; TREATMENT OUTCOME; ULTRASONOGRAPHY; WEIGHT LOSS;

EID: 84970031708     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4178-2     Document Type: Review

References (52)

1. Swinburn BA, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804–814.
2. Peeters A, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138:24–32.
3. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–725. e6.
4. Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811–826.
5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231.
6. Adams LA, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.
7. Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013;18:251–258.
8. Promrat K, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.
9. Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;6:CD003619.
10. Keating SE, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.
11. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255–266.
12. ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy, Ginsberg GG, Chand B, Cote GA, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc. 2011;74:943–953.
13. Abu Dayyeh BK, Thompson CC. Obesity and bariatrics for the endoscopist: new techniques. Therap Adv Gastroenterol. 2011;4:433–442.
14. Imaz I, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–846.
15. Lee YM, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76:756–760.
16. Brunt EM, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820.
17. Folini L, et al. Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. Acta Diabetol. 2014;51:361–368.
18. Forlano R, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71:927–933.
19. Prati D, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.
20. Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–1617.
21. Daniel S, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010–3014.
22. Mathiesen UL, et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999;34:85–91.
23. Marchesini G, et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 2005;28:333–339.
24. Wallace TM, et al. Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. Diabetes Care. 2007;30:2673–2678.
25. Chen Z, Han CK, Pan LL, et al. Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects. Dig Dis Sci. 2014;59:2470–2476.
26. Thamer C, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res. 2005;37:246–251.
27. Lonardo A, et al. Hepatic steatosis and insulin resistance: Does etiology make a difference? J Hepatol. 2006;44:190–196.
28. Lee DS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–133.
29. Yamada J, et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 2006;189:198–205.
30. Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–1286.
31. Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
32. Ponce J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11:874–881.
33. Nikolic M, et al. Obesity treatment using a Bioenterics intragastric balloon (BIB)–preliminary Croatian results. Obes Surg. 2011;21:1305–1310.
34. Diabetes Prevention Program Research, G. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.
35. Chang SH, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149:275–287.
36. Coakley BA, et al. Revisional bariatric surgery for failed restrictive procedures. Surg Obes Relat Dis. 2008;4:581–586.
37. Sjostrom L, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–752.
38. Mathurin P, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–540.
39. Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230–238.
40. Martin M, et al. Socioeconomic disparities in eligibility and access to bariatric surgery: a national population-based analysis. Surg Obes Relat Dis. 2010;6:8–15.
41. Ryou M, et al. Smart Self-Assembling MagnetS for ENdoscopy (SAMSEN) for transoral endoscopic creation of immediate gastrojejunostomy (with video). Gastrointest Endosc. 2011;73:353–359.
42. Thompson CC, et al. Endoscopic suturing for transoral outlet reduction increases weight loss after Roux-en-Y gastric bypass surgery. Gastroenterology. 2013;145:129–137. e3.
43. Ryou M, Ryan MB, Thompson CC. Current status of endoluminal bariatric procedures for primary and revision indications. Gastrointest Endosc Clin N Am. 2011;21:315–333.
44. Sanyal AJ, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344–353.
45. de Jonge C, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:1517–1520.
46. Takihata M, et al. Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients. Obes Res Clin Pract. 2014;8:e331–e338.
47. Tai CM, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg. 2013;23:2068–2074.
48. Zerrweck C, et al. Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients. Obes Surg. 2012;22:777–782.
49. Sekino Y, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med. 2011;50:2449–2455.
50. Stimac D, et al. Intragastric balloon treatment for obesity: results of a large single center prospective study. Obes Surg. 2011;21:551–555.
51. Donadio F, et al. Metabolic parameters after BioEnterics Intragastric Balloon placement in obese patients. J Endocrinol Invest. 2009;32:165–168.
52. Ricci G, et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438–1442.